Takeda taps Schrödinger for drug discovery
Rick Mullin · C&EN Global Enterprise · 2017
Takeda Pharmaceutical has entered a multitarget research collaboration with Schrödinger, a computational science firm. In an effort led by Schrödinger, the Japanese drug firm will provide protein crystal structures to guide the in silico design of new chemical entities in areas of therapeutic interest. Takeda has the option to license compounds from Schrödinger, paying up to $170 million per compound as well as royalties on future sales.